Since radiotherapy is associated with long-term toxicities, including neurocognitive impairment,11–16 their occurrence in patients harboring a grade 3 glioma, IDH-mutant with a long-expected survival is at high risk of impacting the health-related quality of life.17 This questions the possibility of postponing oncological treatments in such patients with favorable clinical and histo-molecular profiles. This evidence concerns the gene IDH1 and central nervous system cancer.